Preparation method and application of IP10-fusion cell vesicle microneedle vaccine with T cell activation function

By combining IP10-fusion cell vesicles with microneedles, an IP10-fusion cell vesicle microneedle vaccine with T-cell activation function was prepared. This solved the problems of insufficient immunostimulatory activity and unsatisfactory delivery methods of existing breast cancer vaccines, achieving efficient immune activation and minimally invasive delivery, and enhancing the clinical application potential of breast cancer vaccines.

CN120960125APending Publication Date: 2025-11-18GUANGXI MEDICAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202511117684.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-11
Publication Date
2025-11-18

AI Technical Summary

Technical Problem

Existing breast cancer vaccines suffer from insufficient immunostimulatory activity, high infection risk due to traditional subcutaneous injection, high cost, and poor patient compliance, making them difficult to widely apply in clinical practice.

Method used

An IP10-fusion cell vesicle microneedle vaccine with T cell activation function was prepared by combining IP10-fusion cell vesicles with microneedles. The vaccine effectively stimulates T cell anti-tumor immune response through the chemotactic effect of IP10 and the antigen presentation function of vesicles, and the vaccine is delivered by utilizing the minimally invasive and sustained-release properties of microneedles.

Benefits of technology

It significantly improved the immune activation effect and patient compliance of the vaccine, reduced the risk of infection, and enhanced the clinical application potential for cancer prevention and treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a preparation method and application of an IP10-fusion cell vesicle microneedle vaccine with a T-cell activation function, IP10-fusion cell vesicles with the T-cell activation function are prepared into the microneedle vaccine, on the immune activation level, the IP10-fusion cell vesicles have a vesicle antigen presentation function through the chemotactic effect of IP10, and the T-cell activation function of the IP10-fusion cell vesicles is achieved. T cell-mediated anti-tumor immune response can be efficiently excited, and a new path is provided for solving the problem of tumor immune escape; in the aspect of a delivery system, the minimally invasive slow release characteristic of the microneedle not only reduces the acceptance resistance of a patient, but also can maintain lasting immunostimulation, and compared with a traditional injection mode, the compliance and the treatment effect of the vaccine are remarkably improved. In addition, good biocompatibility ensures the safety of clinical application, and has great transformation potential in the field of tumor prevention and treatment.
Need to check novelty before this filing date? Find Prior Art